Antibody-Based Therapies for Emerging Infectious Diseases

Emerging Infectious Diseases

Volumn 2, Issue 3, 1996, Pages 200-208

  Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTISERUM; MONOCLONAL ANTIBODY;

ANIMAL; COMMUNICABLE DISEASE; HUMAN; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; HUMANS; IMMUNE SERA;

EID: 0030184441     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0203.960306     Document Type: Article

References (68)

1. Service RF. Antibiotics that resist resistance. Science 1995;270:724-7.
2. Berkelman RL, Bryan RT, Osterholm MT, LeDuc JW, Hughes JM. Infectious disease surveillance: a crumbling foundation. Science 1994;264:368-70.
3. Joshi N, Milfred D. The use and misuse of new antibiotics. Arch Intern Med 1995;155:569-77.
4. Mumford RS, Murphy TV. Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread. J Invest Med 1994;42:613-21.
5. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992;15:508-24.
6. Casadevall A, Scharff MD. "Serum therapy" revisited: animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-702.
7. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-61.
8. Rackemann FM. Allergy: serum reactions, with particular reference to the prevention and treatment of tetanus. JAMA 1942;226:726-33.
9. Feinberg SM. The therapy of (horse) serum reactions, general rules in the administration of therapeutic serums. JAMA 1936;107:1717-9.
10. Finland M. The use of serum, sulfanilamide, and sulfapyridine in the treatment of pneumococcic infections. Med Clin North Am 1939;1205-9.
11. Colebrook L, Maxted WR. Streptococcal infections in mice treated by chemotherapy and serum. Lancet 1940;1:21-8.
12. MacLeod CM. Chemotherapy of pneumococcic pneumonia. JAMA 1939;113:1405-10.
13. Branham SE. Sulphamlamide, serum, and combined drug and serum therapy in experimental meningococcus and pneumococcus infections in mice. Public Health Rep 1938;52:685-95.
14. Sako W, Dwan PF, Platou ES. Sulfanilamide and serum in the treatment and prophylaxis of scarlet fever. JAMA 1938;111:995-7.
15. Alexander HE. Treatment of Haemophilus influenzae infections and of meningococcic and pneumococcic meningitis. Am J Dis Child 1943;66:172-87.
16. Waghelstein JM. Sulfanilamide in the treatment of 106 patients with meningococcic infections. JAMA 1938;111:2172-4.
17. Dowling HF, Abernethy TJ. The treatment of pneumococcus pneumonia: a comparison of the results obtained with specific serum and sulfapyridine. Am J Med Sci 1940;199:55-62.
18. Cory CW, Abbot CE, Truszkowski EG. Treatment of meninogococcic meningitis and septicemia. J Pediatr 1944;25:35-48.
19. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
20. Wright A, Shin S-U, Morrison SL. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 1992;12:125-68.
21. Felton, LD. The units of protective antibody in anti-pneumococcus serum and antibody solution. J Infect Dis 1928;43:531-42.
22. Weisman LE, Cruess DF, Fischer GW. Opsonic activity ofcommercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis J 1994;13:1122-5.
23. Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1994;1:613-9.
24. Lang AB, Cryz SJ, Schurch U, Ganss MT, Bruderer U. Immunotherapy with human monoclonal antibodies. J Immunol 1993;151:466-72.
25. French DL, Laskov R, Scharff MD. The role of somatic hypermutation in the generation of antibody diversity. Science 1989;244:1152-7.
26. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995;63:4211-8.
27. Mukherjee J, Zuckier L, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and m combination with amphotericin B. Antimicrob Agents Chemother 1994;38:580-7.
28. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991;163:1114-20.
29. Mukherjee J, Feldmesser M, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob Agents Chemother 1995;39:1398-405.
30. Feldmesser M, Mukherjee J, Casadevall A. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro. J Antimicrob Chemother. 1996; (in press).
31. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci 1992;89:6901-5.
32. Mineo JR, Khan IA, Kasper LH. Toxoplasma gondii: A monoclonal antibody that inhibits intracellular replication. Experimental Parasitol 1994;79:351-61.
33. Yanase K, Smith RM, Cizman B, Foster MH, Peahy LD, Jarret L, et al. A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleous in a time and temperature-dependent manner. Lab Invest 1994;71:52-60.
34. Heinzel FP. Antibodies. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases New York: Churchill Livingstone, 1995:36-57.
35. Delaet I, Boeye A. Monoclonal antibodies that disrupt poliovirus only at fever temperatures. J Virol 1993;67:5299-302.
36. Smith TW, Butler VP, Haber E, Fozzard H, Marcus FI, Bremmer WF., et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. N Engl J Med 1982;307:1357-62.
37. Bobmer M, Fournel MA, Hinshaw LB. Preclinical review of anti-tumor necrosis factor monoclonal antibodies. Crit Care Med 1993;21:S441-6.
38. Zuckier LS, Rodrigues LD, Scharff MD. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 1989;19:166-86.
39. Waldman TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;14:1-110.
40. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies: pharmaceutical and pharmacokinetic solutions. Clin Phamacokinet 1395;28:126-42.
41. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, et al. Mouse/human chimeric monoclonal antibody in man:kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
42. Pennington JE. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother 1990;34:1463-6.
43. Pasatiempo AMG, Kroser JA, Rudnick M, Hoffman BI. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994;21:347-9.
44. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
45. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 1993;118:937-42.
46. Bullowa JGM. The management of the pneumonias. New York:Oxford University Press, 1937.
47. Bullowa JGM. The reliability of sputum typing and its relation to serum therapy. JAMA 1935;105:1512-8.
48. Sadziene A, Rosa PA, Thompson PA, Hogan DM, Barbour AG. Antibody-resistant mutants of Borrelia burgdorferi: In vitro selection and characterization. J Exp Med. 1992;176:799-809.
49. Halter R, Pohlner J, Meyer TF. Mossaic-like organization of IgA protease genes in Neisseria gonorrhoeae generated by horizontal genetic exchange in vivo. EMBO J 1989;8;2737-44.
50. Barnes GL, Doyle LW, Hewson PH, et al. A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet 1982;1:1371-3.
51. Borowitz SM, Saulsbury FT. Treatment of chronic cryptosporidial infection with orally admininstered human serum immune globulin. J Pediatr 1991;119:593-5.
52. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
53. Lazarovits AI, Rochon J, Banks L, Hollomby DJ, Muirhead N, Jevnikar AM, et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 1993;150:5163-74.
54. Issacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, et al. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
55. Hoyne AL. Intravenous treatment of meningococcic meningitis with meningococcus antitoxin. JAMA 1936;107:478-81.
56. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913;17:553.
57. Triguro D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci 1989;86:4761-5.
58. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug complexes cross the blood-brain barrier. Proc Natl Acad Sci 1991;88:4771-5.
59. Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch Surg 1994;129:443-7.
60. Wolff SM. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock. N Engl J Med 1991;324:486-7.
61. Fink MP. Adoptive immunotherapy of gram-negative sepsis:use of monoclonal antibodies to lipopolysaccharide. Crit Care Med 1994;21:S32-9.
62. Loewenthal L, Berlin MD. Combined serum and sulphanilamide in the treatment of streptococcal infections in mice. Lancet 1939;1:197-9.
63. Klemperer G and Klemperer F. Versuche uber immunisirung und heilung bei der pneumokokken-infection. Berl Klin Wochenschr 1891;28:833-5.
64. Bullowa JGM. Serum Therapy. In: The management of the pneumonias, New York: Oxford University Press, 1937:283-362.
65. Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the pneumococeus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 1993;17:913-24.
66. Devi SJN, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991;59:3700-7.
67. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992;60:4534-41.
68. Pier GB, Thomas D, Small G, Siadak A, Zweerink H. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeroginosa lipopolysaccharide. Infect Immun 1989;57:174-9.